We have located links that may give you full text access.
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
RESEARCH SUPPORT, NON-U.S. GOV'T
Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial.
Journal of Ayub Medical College, Abbottabad : JAMC 2007 October
BACKGROUND: The tolerability and efficacy for patients with obsessive-compulsive disorder (OCD) in a large, sample on Escitalopram was studied.
METHODS: A total of 100 adults with a confirmed diagnosis of OCD were included. The percentage of patients with an adequate drug trial, defined as 42 days of continuous treatment with a serotonin- reuptake inhibitor or placebo at dosages at or above established minimal effective dosages.
RESULTS: Ninety-six percent of the adults who were newly diagnosed with OCD in the index year had an adequate trial of medication after their first visit for OCD. By the second half of 42 days the patient who were responding to the treatment were randomly allocated to two groups. One group received the same drug and other group was given placebo. The results were complied at the end of three months of each patient treatment. No additional psychotherapy was offered to these patients during this time period.
CONCLUSIONS: Despite the typically chronic course of OCD, many patients with OCD responded to the Esciatolpram at the dosage of twenty milligram per day.
METHODS: A total of 100 adults with a confirmed diagnosis of OCD were included. The percentage of patients with an adequate drug trial, defined as 42 days of continuous treatment with a serotonin- reuptake inhibitor or placebo at dosages at or above established minimal effective dosages.
RESULTS: Ninety-six percent of the adults who were newly diagnosed with OCD in the index year had an adequate trial of medication after their first visit for OCD. By the second half of 42 days the patient who were responding to the treatment were randomly allocated to two groups. One group received the same drug and other group was given placebo. The results were complied at the end of three months of each patient treatment. No additional psychotherapy was offered to these patients during this time period.
CONCLUSIONS: Despite the typically chronic course of OCD, many patients with OCD responded to the Esciatolpram at the dosage of twenty milligram per day.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app